Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 11;11(2):30.
doi: 10.1038/s41408-021-00424-4.

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

Konstantinos Liapis  1 , Vasileios Papadopoulos  2 , George Vrachiolias  2 , Athanasios G Galanopoulos  3 , Menelaos Papoutselis  2 , Sotirios G Papageorgiou  4 , Panagiotis T Diamantopoulos  5 , Vassiliki Pappa  4 , Nora-Athina Viniou  5 , Alexandra Kourakli  6 , Dimitris Τsokanas  3 , Theodoros P Vassilakopoulos  7 , Eleftheria Hatzimichael  8 , Eleni Bouronikou  9 , Maria Ximeri  10 , Charalambos Pontikoglou  10 , Aekaterini Megalakaki  11 , Panagiotis Zikos  12 , Panayiotis Panayiotidis  13 , Maria Dimou  13 , Stamatis Karakatsanis  14 , Maria Papaioannou  15 , Anna Vardi  16 , Flora Kontopidou  17 , Nikolaos Harchalakis  18 , Ioannis Adamopoulos  19 , Argiris Symeonidis  6 , Ioannis Kotsianidis  2
Affiliations

Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes

Konstantinos Liapis et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

I.K., N.A.V., A.S., E.H. and Vasiliki Pappa have received research funding from Celgene Corporation (of no relevance to this study). I.K., S.G.P., T.P.V., A.G.G., E.H., P.P., A.K., A.S., Vasiliki Pappa, and N.A.V. have received honoraria from Genesis Pharma Hellas S.A. (of no relevance to this study). All other authors have no conflicts of interest.

Figures

Fig. 1
Fig. 1. Kaplan–Meier analysis of survival outcomes in patients with intermediate-risk MDS.
(A) Kaplan–Meier curves of OS for patients with intermediate-risk MDS according to their IPSS-R value (3.5, 4.0, or 4.5). OS was better among patients with IPSS-R 3.5 as compared with IPSS-R > 3.5 (p = 0.039 by the log-rank test). (B) Kaplan-Meier curve of OS among patients with intermediate-risk MDS who received AZA (n = 166), as compared with patients who did not (n = 302). Median OS of the patients who received AZA (32.4 months [95% CI 25.2–39.6]) was similar to patients who did not receive AZA (29.0 months [23.9–34.1]); p = 0.291 by the log-rank test. (C) Kaplan-Meier curve of LFS among patients with intermediate-risk MDS who received AZA (n = 166), as compared with patients who did not (n = 302). Median LFS was 28.0 months (95% CI 19.0–37.0) for the AZA group and 26.0 months (21.8–30.2) for the non-AZA-treated group (p = 0.188). MDS myelodysplastic syndrome, OS overall survival, IPSS-R revised international prognostic scoring system, AZA azacitidine, LFS leukemia-free survival.
See this image and copyright information in PMC

References

    1. Greenberg PL, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–2465. doi: 10.1182/blood-2012-03-420489. - DOI - PMC - PubMed
    1. Benton CB, et al. Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R. Am. J. Hematol. 2018;93:1245–1253. doi: 10.1002/ajh.25234. - DOI - PMC - PubMed
    1. Pfeilstöcker M, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128:902–910. doi: 10.1182/blood-2016-02-700054. - DOI - PMC - PubMed
    1. Vidaza (azacitidine) [package insert]. Uxbridge, UK: Celgene Ltd (2019).
    1. Merz A, et al. EASIX for prediction of survival in lower-risk myelodysplastic syndromes. Blood Cancer J. 2019;9:85. doi: 10.1038/s41408-019-0247-z. - DOI - PMC - PubMed

Publication types

Substances